Michael Atkins, MD, of Georgetown University, Washington DC, outlines the results of the study of VEGF inhibitor axitinib in combination with pembrolizumab for the first-line treatment of advanced renal cell cancer (NCT02133742). Dr Atkins goes onto explain the next steps required for this result to impact treatment, and eagerly awaits the results of the KEYNOTE-426 trial (NCT02853331). This interview took place at the 2018 Genitourinary Cancers Symposium in San Francisco, CA.
Promising results for axitinib and pembrolizumab in advanced renal cell cancer
